Clinical Trials Logo

Clinical Trial Summary

This study will assess the efficacy of mirabegron, a new beta3-adrenergic receptor in the prevention of heart failure. This is a two armed, prospective, randomized, placebo-controlled, multi-centric european phase IIb trial with placebo and mirabegron distributed in a 1:1 fashion. The patients enrolled will have cardiac structural remodeling with or without symptoms of heart failure (maximum NYHA II). Patients will be monitored for change in left ventricular mass (assessed by cardiac MRI) and/or changes in diastolic function (assessed by echocardiography) after 12 months of treatment.


Clinical Trial Description

Background Heart failure (HF) represents a major and growing public health burden. Patients with HF are classically divided into two groups: those with HF with preserved ejection fraction (HFpEF), and those with HF and reduced ejection fraction (HFrEF). As HF is a progressive disorder increasing with age, the proportion of these patients is rising due to the aging of the population. Beside costs, HFpEF also puts a heavy burden on the quality of life of (mostly elderly) patients, with a loss of autonomy and the dyscomfort of repeated hospitalisations. Therefore, HFpEF is a chronic, costly, debilitating disease. A major contributor to HFpEF is myocardial remodelling, e.g. hypertrophy and fibrosis, as well as cellular functional/structural modifications leading to alteration in contractile properties and ventricular distensibility. Unfortunately, there are currently no evidence-based treatment strategies. Study claim The proposed clinical trial will provide a proof of concept in humans for the clinical efficacy of a novel therapeutic concept: β3AR activation to attenuate/prevent cardiac remodeling. Recently, a new, specific agonist at human β3-AR (mirabegron) with higher benefit/risk balance was developed and marketed for clinical use in a non-cardiovascular disease (overactive bladder disease). The trial will test the drug repurposing of mirabegron for the prevention of cardiac remodeling leading to HFpEF. Using pre-clinical models, the investigators demonstrated that activation of β3AR attenuates myocardial hypertrophy and fibrosis in response to neurohormonal or hemodynamic stresses, without compromising LV function. Therefore, the recent availability of this new drug offers the possibility to test the potential benefit of mirabegron (vs placebo) as add-on therapy (on top of standard care) to prevent/delay myocardial remodelling in patients at high risk of developing HFpEF. Who can participate? Patients with structural cardiac disease with or without HF symptoms (max. NYHA 2). What does the study involve? Patients will be requested to go 5 times to the hospital to perform cardiac MRI (3X), echocardiography (3X), exercise tolerance test (2X), Pet scanning (2X) and blood sampling (4X). Who is the sponsor? The Université catholique de Louvain (UCL) is the academic sponsor and Prof. Jean-Luc Balligand is the principal coordinator of the study. Who is funding the study? Beta3_LVH is an investigator-initiated project funded by a Horizon 2020 grant from the European Commission. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02599480
Study type Interventional
Source Université Catholique de Louvain
Contact
Status Active, not recruiting
Phase Phase 2
Start date April 2016
Completion date September 2022

See also
  Status Clinical Trial Phase
Completed NCT02237339 - Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension? Phase 4
Completed NCT00041418 - Cardiac MR of Subclinical CVD: Impact of Age N/A
Completed NCT00005373 - Racial Differences in the Coronary Microcirculation N/A
Recruiting NCT00989508 - Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy Phase 2/Phase 3
Completed NCT03482934 - Predictors of Left Ventricular Hypertrophy in Hypertensive Patients in Assiut Governorate
Completed NCT03415750 - Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants Phase 4
Completed NCT02973607 - Effects of a Reduction in Renal Function on Cardiovascular Structure and Function
Completed NCT03749551 - Towards Understanding the Phenotype of Cardiovascular Disease in CKD - TRUE-Type-CKD Study
Completed NCT01976689 - New-onset Diabetes and Left Ventricular Hypertrophy in Renal Transplantation N/A
Active, not recruiting NCT05713916 - Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy N/A
Recruiting NCT00552851 - Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Phase 4
Active, not recruiting NCT03094143 - Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients With Severe AS N/A
Completed NCT02444689 - EMPower: Electronic Media Powering Positive Health Changes in Youth N/A
Terminated NCT00616902 - The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5 Phase 3
Completed NCT00108082 - The CLEVER Study - Coreg And Left Ventricular Mass Regression Phase 3
Withdrawn NCT03315832 - Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study Phase 2/Phase 3
Completed NCT03180593 - Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH Phase 4
Completed NCT01144039 - Glutamate and Diastolic Function in Patients Undergoing Aortic Valve Repair Phase 4
Completed NCT00045994 - The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling Phase 2
Active, not recruiting NCT04862273 - Native T1 CMR Imaging for Diagnosis of Cardiac Amyloidosis